Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 Directed Dendritic Cell Vaccine in Neoadjuvant Therapy of HER2+ Breast Cancer
NCT03387553Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2018
- Primary completion
- Aug 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of DC1 in HER2-positive breast cancer (3 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Expansion Phase Schedule Selection at 4 weeks and Pathologic Complete Response Rate at 28 weeks. Started Jun 2018; status: completed.
02
Drugs
DC1
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03387553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387553.